Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Ascending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
30698-0201-30 30698-0201 Bromocriptine Mesylate Parlodel 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
30698-0202-01 30698-0202 Bromocriptine Mesylate Parlodel 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
30698-0202-30 30698-0202 Bromocriptine Mesylate Parlodel 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 28, 2014 In Use
60687-0286-11 60687-0286 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral July 7, 2017 In Use
60687-0286-21 60687-0286 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral July 27, 2017 Sept. 30, 2024 In Use
51144-0050-01 51144-0050 Brentuximab vedotin Adcetris 50.0 mg/10.5mL Immunotherapy Drug Antibody Conjugate CD30 Intravenous Aug. 25, 2011 In Use
00008-0100-01 00008-0100 Inotuzumab Ozogamicin Besponsa 0.25 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Aug. 18, 2017 In Use
50242-0103-01 50242-0103 polatuzumab vedotin POLIVY 30.0 mg/1.88mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous Sept. 18, 2020 In Use
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec. 20, 2019 In Use
50242-0105-01 50242-0105 polatuzumab vedotin POLIVY 140.0 mg/7.52mL Immunotherapy Drug Antibody Conjugate CD79b Intravenous June 10, 2019 In Use
55135-0132-01 55135-0132 SACITUZUMAB GOVITECAN TRODELVY 180.0 mg/1 Immunotherapy Drug Antibody Conjugate Trop-2 Intravenous April 23, 2020 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
51144-0003-01 51144-0003 Tisotumab vedotin TIVDAK 40.0 mg/4mL Immunotherapy Drug Antibody Conjugate Tissue factor Intravenous Sept. 20, 2021 In Use
51144-0020-01 51144-0020 ENFORTUMAB VEDOTIN PADCEV 20.0 mg/2mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
51144-0030-01 51144-0030 ENFORTUMAB VEDOTIN PADCEV 30.0 mg/3mL Immunotherapy Drug Antibody Conjugate Nectin-4 Intravenous Dec. 18, 2019 In Use
00008-4510-01 00008-4510 Gemtuzumab ozogamicin Mylotarg 5.0 mg/5mL Immunotherapy Drug Antibody Conjugate CD33 Intravenous Sept. 7, 2017 In Use
72903-0853-01 72903-0853 Mirvetuximab soravtansine ELAHERE 100.0 mg/20mL Immunotherapy Drug Antibody Conjugate FR-alpha, DM4 Intravenous Nov. 14, 2022 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb. 22, 2013 In Use
79952-0110-01 79952-0110 loncastuximab tesirine ZYNLONTA 10.0 mg/2mL Immunotherapy Drug Antibody Conjugate CD19 Intravenous April 30, 2021 In Use
00173-0896-01 00173-0896 Belantamab Blenrep 50.0 mg/mL Immunotherapy Drug Antibody Conjugate BCMA Intravenous Aug. 5, 2020 June 30, 2024 In Use
00310-4700-01 00310-4700 moxetumomab pasudotox LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous Oct. 24, 2018 Sept. 30, 2024 In Use
59572-0705-30 59572-0705 Enasidenib mesylate Idhifa 50.0 mg/1 Chemotherapy Enzyme Inhibitor IDH2 Oral Aug. 1, 2017 In Use
59572-0710-30 59572-0710 Enasidenib mesylate Idhifa 100.0 mg/1 Chemotherapy Enzyme Inhibitor IDH2 Oral Aug. 1, 2017 In Use
61958-1701-01 61958-1701 Idelalisib Zydelig 100.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use

Found 10,000 results in 10 millisecondsExport these results